Compare Las Vegas Sands Corp. (LVS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Tango Therapeutics Inc. — how do they compare? Las Vegas Sands Corp. trades at $36.76 (market cap $23.98B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Las Vegas Sands Corp. is far larger — about 6.4× Tango Therapeutics Inc.'s market cap, and Las Vegas Sands Corp. pays a 3.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 73 Days and Tango Therapeutics Inc. for 0 Days on average.
| LVS | TNGX | |
|---|---|---|
Market Cap | $23.98B | $3.74B |
Volume | 5,962,073 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $32.90 |
52-Week Low | $35.81 | $7.50 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $35.86B | $2.76B |
Dividend Yield | 3.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $37.04, up 2.46% today, amid a bearish technical signal. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $58.89 price target, indicating significant upside potential. Recent news highlights Sands China's community initiatives and operational milestones, reinforcing its market presence.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and market volatility. Investment opportunity lies in the valuation discount relative to growth prospects, though investors should monitor earnings consistency and macroeconomic factors affecting the gaming and hospitality sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
